p-mTOR、p-4EBP1及p-S6K1在结直肠腺癌组织中的表达及临床意义

doi:10.13418/j.issn.1001-165x.2022.5.08

中国临床解剖学杂志 ›› 2022, Vol. 40 ›› Issue (5): 541-547.doi: 10.13418/j.issn.1001-165x.2022.5.08

p-mTOR、p-4EBP1及p-S6K1在结直肠腺癌组织中的表达及临床意义

曹李^1,2，陈鹏²，李丁昌²，董光龙²*

1.南开大学医学院，天津 300071； 2.解放军总医院第一医学中心普通外科医学部，北京 00853

收稿日期:2021-03-03 出版日期:2022-09-25 发布日期:2022-10-11
通讯作者: 董光龙，主任医师，博士生导师，E-mail：gldong301@163.com
作者简介:曹李（1984-），男，河北张家口人，博士在读，主治医师，研究方向：大肠肿瘤转移免疫学机制，E-mail：jiefangjun1984@163.com
基金资助:
国家自然科学基金面上项目（81773247）

Expression and clinical significance of p-mTOR, p-4EBP1 and p-S6K1 in colorectal adenocarcinoma

Cao Li^1,2, Chen Peng², Li Dingchang², Dong Guanglong²*

1.Nankai University School of Medicine，Tianjing 300071,China; 2.Department of General Surgery，First Medical Center, General Hospital of PLA, Beijing 100853，China

Received:2021-03-03 Online:2022-09-25 Published:2022-10-11

摘要/Abstract

摘要： 目的研究p-mTOR、p-4EBP1及p-S6K1在结直肠腺癌发生、发展过程中可能的作用及临床意义。方法应用免疫组化检测60例结直肠腺癌组织及40例癌旁正常组织中p-mTOR、p-4EBP1及p-S6K1的表达情况，比较各组差异，分析其与相关临床病理特征的关系，阳性率间相关性分析采用Spearman相关分析检验，检验水准α=0.05。结果 p-mTOR、p-4EBP1及p-S6K1在结直肠腺癌组织中表达水平均高于癌旁组织，差异有统计学意义（P<0.05）。p-mTOR的表达与患者的淋巴结转移、TNM分期及分化程度有关（P<0.05）。p-S6K1的表达与患者的TNM分期及分化程度有关（P<0.05）。p-mTOR与p-4EBP1在结直肠腺癌组织中的表达有一定的正相关性（P<0.05）。p-mTOR与p-S6K1在结直肠腺癌组织中的表达有明显的正相关性（P<0.05）。结论 p-mTOR、p-4EBP1及p-S6K1在结直肠腺癌粘膜组织中过度表达可能是结直肠腺癌发生的重要机制之一，此三种磷酸化蛋白与结直肠腺癌的发生发展存在某种内在关联。

关键词: 结直肠腺癌； , , p-mTOR； , , p-4EBP1； , , p-S6K1； , , 免疫组化

Abstract: Objective To study the expression of p-mTOR, p-4EBP1 and p-S6K1 in colorectal adenocarcinoma and adjacent tissues and analyze their relationship with relevant clinicopathological data, and explore their occurrence and development in colorectal adenocarcinoma and the possible role and clinical significance. Methods Immunohistochemistry was used to detect the expression of p-mTOR, p-4EBP1 and p-S6K1 in 60 cases of colorectal adenocarcinoma tissues and 40 cases of adjacent normal tissues, compare the differences of each group, and analyze their relationship with relevant clinicopathological characteristics. The positive rate correlation analysis was performed by Spearman correlation analysis, and the test level α=0.05. Results The expression levels of p-mTOR, p-4EBP1 and p-S6K1 in colorectal adenocarcinoma tissues were higher than those in adjacent tissues on average, with statistically significant differences (P<0.05). The expression of p-mTOR was related to the stage of patients with lymph node metastasis, TNM stage and differentiation degree (P<0.05). The expression of p-S6K1 was related to the TNM stage and differentiation degree of the patient (P<0.05). The expression of p-mTOR and p-4EBP1 in colorectal adenocarcinoma tissue has a certain positive correlation (P<0.05), and the expression of p-mTOR and p-S6K1 in colorectal adenocarcinoma tissue has a significant positive correlation (P<0.05). Conclusions The overexpression of p-mTOR, p-4EBP1 and p-S6K1 in the mucosal tissue of colorectal adenocarcinoma may be one of the important mechanisms for the occurrence of colorectal adenocarcinoma. These three phosphorylated proteins may be related to the occurrence and development of colorectal adenocarcinoma.

Key words: Nasopharyngeal carcinoma; , , Drug resistance; , , Micro RNA; , Cisplatin; , Cyclin protein

中图分类号:

R766.3

曹李, 陈鹏, 李丁昌, 董光龙. p-mTOR、p-4EBP1及p-S6K1在结直肠腺癌组织中的表达及临床意义[J]. 中国临床解剖学杂志, 2022, 40(5): 541-547.

Cao Li, Chen Peng, Li Dingchang, Dong Guanglong. Expression and clinical significance of p-mTOR, p-4EBP1 and p-S6K1 in colorectal adenocarcinoma[J]. Chinese Journal of Clinical Anatomy, 2022, 40(5): 541-547.

参考文献 20

[1]	中华人民共和国国家卫生健康委员会医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2020年版)[J]. 中国实用外科杂志, 2020, 40(6): 601-625. DOI: 10.19538/j.cjps.issn1005-2208.2020.06.01.
[2]	汤国辉, 贺修胜. 结直肠癌相关长链非编码RNA的研究进展[J]. 中南医学科学杂志, 2018, 46(3): 241-246. DOI: 10.15972/j.cnki.43-1509/r.2018.03.004.
[3]	Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism[J]. Cell, 2006, 124(3): 471-484. DOI: 10.1016/j.cell. 2006. 01.016.
[4]	Francipane MG, Lagasse E. mTOR pathway in colorectal cancer: an update[J]. Oncotarget, 2014, 5(1): 49-66. DOI: 10.18632/oncotarget. 1548.
[5]	Zhang YJ, Dai Q, Sun DF, et al. mTOR signaling patnway is a target for the treatment of colorectal cancer[J]. Ann Surg Oncol, 2009, 16(9): 2617-2628. DOI: 10.1245/s10434-009-0555-9.
[6]	Zhu Y, Jiang HG, Chen ZH, et al. Short-term efficacy of laparoscopic treatment for colorectal cancer in patients with schistosomiasis japonica[J]. Gastroenterol Res Pract, 2016, 2016: 8357025. DOI: 10.1155/2016/8357025.
[7]	O’Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptortyrosine kinase signaling and activates Akt[J]. Cancer Res, 2006, 66(3): 1500-1508. DOI: 10.1158/0008-5472.CAN-05-2925.
[8]	Wallin JJ, Edgar KA, Guan J, et al. GDC-0980 is a novel classⅠPI3K/mTOR kinase inhhibitor with robust activity in cancer models driven by the PI3K pathway[J]. Mol Cancer Ther, 2011, 10(12): 2426-2436. DOI: 10.1158/1535-7163.MCT-11-0446.
[9]	Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity[J]. Mol Cancer Ther, 2008, 7(7): 1851-1863. DOI: 10.1158/1535-7163.MCT-08-0017.
[10]	Dobbelstein M, Moll U. Targeting tumour-supportive cellular machineries in anticancer drug development[J]. Nat Rev Drug Discov, 2014, 13(3): 179-196. DOI: 10.1038/nrd4201.
[11]	Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth[J]. Nature, 2006, 441(7092): 424-430. DOI: 10.1038/nature04869.
[12]	Hay N, Sonenberg N. Upstream and downstream of mTOR[J]. Genes Dev, 2004, 18(16): 1926-1945. DOI: 10.1101/gad.1212704.
[13]	Beca F, Andre R, Martins DR, et al. p-mTOR expression is associated with better prognosis in luminal breast carcinoma[J]. J Clin Pathol, 2014, 67(11): 961-967. DOI: 10.1136/jclinpath-2014-202320.
[14]	Slattery ML, Herrick JS, Lundgreen A, et al. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: Mtor, PTEN, STK11, RPKAA1, PRKAG2, TSC1, PI3K, and Akt1[J]. Gareinogenesis, 2010, 39(1): 1604-1611. DOI: 10.1093/carcin/bgq142.
[15]	王茜, 时延龙, 毕经旺. p-mTOR与HIF-1α在结直肠癌组织中的表达及其临床意义[J]. 中国肿瘤生物治疗杂志, 2015, 22(6): 779-784. DOI: 10.3872/j.issn.1007-385X.2015.06.017.
[16]	赵长林, 胡芳娟, 曹红霞, 等. 直肠癌组织中mTOR和VEGF的表达与侵袭转移及预后的关系[J]. 临床肿瘤学杂志, 2012, 17(10): 899-903. DOI: 10.3969/j.issn.1009-0460.2012.10.008.
[17]	张毅, 张甘露, 王俊红, 等. 直肠癌组织Akt-mTOR蛋白表达与临床病理因素相关性分析[J]. 中华肿瘤防治杂志, 2013, 20(4): 296-300. DOI:CNKI:SUN:LCZL.0.2012-10-008.
[18]	West MG, Stoneley M, Willis AE, et al.Translation induction of the c-myc oncogene via activation of the FRAP/TOR signaling pathway[J]. Oncogene, 1998, 17(6): 769-780. DOI: 10.1038/sj.onc.1201990.
[19]	Populo H, Soares P, Faustino A, et al. mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics[J]. Pigment Cell Melanoma Res, 2011, 24(1): 254-257. DOI: 10.1111/j.1755-148X.2010.00796.x.
[20]	No JH, Jeon YT, Park IA, et al. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer[J]. Gynecol Oncol,2011, 121(1):8-12. DOI: 10.1016/j.ygyno. 2010. 12.364.

p-mTOR、p-4EBP1及p-S6K1在结直肠腺癌组织中的表达及临床意义

Expression and clinical significance of p-mTOR, p-4EBP1 and p-S6K1 in colorectal adenocarcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 20

相关文章 15

Metrics

本文评价

推荐阅读 0

[1]	江剑宏, 段仁鹏, 李晓锋. 国人胆道三维重建解剖变异应用研究[J]. 中国临床解剖学杂志, 2024, 42(1): 1-4.
[2]	郭红志, 王瑜, 张加琪, 梁海彬, 马梓玮, 冯伟, 吴忧, 司子燚. 血管铸型结合CT三维模型评估先兆子痫胎盘血管结构[J]. 中国临床解剖学杂志, 2024, 42(1): 5-10.
[3]	李佳伟, 张静, 李灿然, 兰文杰, 籍庆余, 郭志勇, 张云凤, 刘启, 陈清威, 李筱贺. 蒙古族人群股骨近端解剖参数X线测量[J]. 中国临床解剖学杂志, 2024, 42(1): 11-16.
[4]	李琨, 张燕, 郭冉, 郝咪咪, 吴轩宇, 徐艺芳, 王超群, 马文童, 张灵淇, 杨宏宇, 李志军, 张少杰, 王星. 儿童及青少年枕颈角与后枕颈角数字化测量及其临床意义[J]. 中国临床解剖学杂志, 2024, 42(1): 17-20.
[5]	李文, 杨思艺, 黄蕾, 卿霁雯, 蒋松涛, 张磊. 基于MRI探讨Lisfranc韧带的形态学特点及临床意义[J]. 中国临床解剖学杂志, 2024, 42(1): 21-25.
[6]	李凡凡, 徐阳, 王晓旭. 紫草素调节Nrf2/HO-1信号通路对实验性大鼠肉芽肿性小叶性乳腺炎的治疗作用研究[J]. 中国临床解剖学杂志, 2024, 42(1): 26-32.
[7]	王兴航, 丁佳媛, 李放, 包翠芬, 阎丽菁. 人参皂苷Rg1通过抑制NLRP3炎症小体途径减轻氧糖剥夺/复供后小胶质细胞炎症反应[J]. 中国临床解剖学杂志, 2024, 42(1): 33-41.
[8]	程莹莹, 武建军, 蔡海燕, 焦旭文, 马江波, 丁银秀. 体外炎性诱导星形胶质细胞激活及功能分析[J]. 中国临床解剖学杂志, 2024, 42(1): 42-46.
[9]	祁志, 杨力, 贾秋叶, 陈浩伦, 段兆达, 吴春云. 依达拉奉经MAPKs通路对脂多糖激活的小胶质细胞Sirt3表达调控[J]. 中国临床解剖学杂志, 2024, 42(1): 47-53.
[10]	张晶晶, 王洪新. 黄芩苷通过PDGF/P38 MAPK信号通路对肺动脉高压大鼠的保护作用[J]. 中国临床解剖学杂志, 2024, 42(1): 54-58.
[11]	乐钦, 陈荣丽, 熊婧熙, 王婷怡, 蔡志恒, 易秋实, 曾心怡. 白芨多糖对大鼠跨区皮瓣choke区的影响[J]. 中国临床解剖学杂志, 2024, 42(1): 59-64.
[12]	李笑予, 张磊, 付磊, 李东波, 汪国友. 三步接骨法治疗Sanders Ⅱ型跟骨骨折的有限元研究[J]. 中国临床解剖学杂志, 2024, 42(1): 65-70.
[13]	吴研飞, 马剑雄, 卢斌, 王颖, 柏豪豪, 靳洪震, 马信龙. CT后处理技术重建CT值与终板抗压强度的相关性研究[J]. 中国临床解剖学杂志, 2024, 42(1): 71-76.
[14]	庄万强, 唐毅, 骆勇刚, 张辉. 关节镜联合胫骨高位截骨术对髌骨位置及髌股关节功能影响的早中期回顾性研究[J]. 中国临床解剖学杂志, 2024, 42(1): 77-82.
[15]	罗鹰, 窦伟誉, 吴小杭, 陈璟昆, 彭昌贵, 潘剑英 . 微创海马钢板内固定治疗跟骨骨折并发症的影响因素[J]. 中国临床解剖学杂志, 2024, 42(1): 83-88.